Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PIMAVANSERIN vs ACTIQ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Pimavanserin is a selective serotonin 5-HT2A receptor inverse agonist and antagonist, with no affinity for dopamine receptors, modulating glutamate and dopamine signaling in the cortex and striatum.
Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.
Treatment of hallucinations and delusions associated with Parkinson's disease psychosis (FDA-approved)
Management of breakthrough pain in cancer patients aged 16 and older who are already receiving and tolerant to opioid therapy for their underlying persistent cancer pain
34 mg orally once daily.
200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.
Terminal elimination half-life is approximately 50 hours, allowing once-daily dosing; steady state reached in about 2 weeks.
Terminal half-life 0.83–2 hours (mean 1.3 h) in adults; note that context: transmucosal absorption leads to rapid onset but short duration; half-life is not correlated with clinical effect due to oral transmucosal route and rapid redistribution.
Primarily metabolized by CYP3A4 and CYP3A5, with minor contributions from CYP2J2 and CYP2D6. The major metabolite is N-desmethylpimavanserin, which is pharmacologically active.
Primarily hepatic via CYP3A4 to inactive metabolites (norfentanyl, despropionylfentanyl, hydroxyfentanyl) and other metabolites; <7% excreted unchanged in urine.
Primarily hepatic metabolism, with approximately 60% excreted in feces and 20% in urine as metabolites; less than 5% excreted as unchanged drug.
Primarily renal as metabolites (about 75% as metabolites, <10% unchanged). Fecal excretion accounts for <9%. Biliary excretion is minor.
Approximately 95% bound to plasma proteins, primarily albumin.
Fentanyl is 80–85% bound to plasma proteins (primarily albumin and α1-acid glycoprotein).
Volume of distribution is approximately 400 L (about 4.7 L/kg), indicating extensive extravascular distribution.
Approximately 4 L/kg (range 3–6 L/kg); large Vd indicates extensive tissue distribution and redistribution contributing to short duration.
Oral bioavailability is approximately 20% due to extensive first-pass metabolism.
Oral transmucosal: 50% (range 47–54%) relative to IV; variable and enhanced by rapid absorption through buccal mucosa.
No dose adjustment required for mild to moderate renal impairment. Not recommended in severe renal impairment (e GFR <30 m L/min/1.73 m²) due to lack of data.
No specific GFR-based dose adjustment recommended; use with caution in severe renal impairment (Cr Cl < 30 m L/min) and consider dose reduction due to potential accumulation.
No dose adjustment for mild hepatic impairment (Child-Pugh class A). Not recommended in moderate to severe hepatic impairment (Child-Pugh class B or C) due to increased exposure and risk of QT prolongation.
Child-Pugh Class A/B: No adjustment. Child-Pugh Class C: Reduce initial dose to 100 mcg and titrate slowly; monitor closely for prolonged effects.
Safety and efficacy not established in pediatric patients (<18 years). No dosing recommendation.
Not approved for pediatric use; safety and efficacy not established in patients under 16 years.
No specific dose adjustment; use caution due to potential increased sensitivity and risk of QT prolongation. Monitor renal function and electrolytes.
Initiate at 100 mcg transmucosally; titrate slowly due to increased sensitivity and risk of respiratory depression. Monitor for adverse effects.
No FDA boxed warning.
Risk of respiratory depression, addiction, abuse, and misuse; accidental ingestion can be fatal; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death; not for use in opioid non-tolerant patients; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; serious, life-threatening, or fatal respiratory depression may occur even at recommended doses.
Risk of QT interval prolongation; avoid use in patients with known QT prolongation or with drugs that prolong QT interval.,Not recommended for use in patients with severe hepatic impairment (Child-Pugh Class C).,May cause somnolence, orthostatic hypotension, and gastrointestinal effects.,Gradual dose titration recommended to minimize adverse effects.
Risk of respiratory depression; addiction, abuse, and misuse; interactions with CNS depressants; serotonin syndrome; adrenal insufficiency; severe hypotension; seizures; withdrawal; use in patients with head injuries, increased intracranial pressure, biliary tract disease, pancreatitis; risk of choking with lozenge; oral mucosal irritation; dental caries; hypokalemia; hyponatremia; use in elderly, cachectic, or debilitated patients.
Known hypersensitivity to pimavanserin or any of its components.,Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole) due to increased exposure and risk of QT prolongation.,Concomitant use with strong CYP3A4 inducers (e.g., rifampin) may reduce efficacy.
Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known or suspected paralytic ileus; hypersensitivity to fentanyl or any component; opioid non-tolerant patients; management of acute or postoperative pain including headache/migraine, dental pain, or emergency department use.
Avoid grapefruit and grapefruit juice due to potential for increased pimavanserin exposure and QT prolongation risk. No other significant food interactions reported.
No significant food interactions. Grapefruit juice may increase fentanyl levels, but specific studies with ACTIQ are lacking. Avoid alcohol, as it may increase sedation and respiratory depression risk.
Pimavanserin is classified as Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. In animal reproduction studies, no evidence of fetal harm was observed at doses up to 8 times the maximum recommended human dose. However, because animal studies are not always predictive of human response, pimavanserin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. First trimester risks are unknown; second and third trimester risks are not characterized. Use caution.
FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause neonatal opioid withdrawal syndrome; avoid use during labor due to risk of neonatal respiratory depression.
It is not known whether pimavanserin is excreted in human milk. The molecular weight (approx. 540 Da) suggests possible excretion. No data on M/P ratio. Due to the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
Excreted in breast milk; M/P ratio not established. Limited data suggest low levels, but risk of infant sedation and respiratory depression. Avoid use while breastfeeding unless potential benefit outweighs risk.
No pharmacokinetic studies in pregnant women are available. Dose adjustments are not established. Use the lowest effective dose if treatment is deemed necessary during pregnancy.
Due to increased plasma volume and hepatic metabolism in pregnancy, dose requirements may increase; adjust based on clinical response and tolerance. Avoid use during labor and delivery due to risk of neonatal respiratory depression; short-term use preferred.
Pimavanserin is a 5-HT2A inverse agonist approved for Parkinson's disease psychosis. It does not worsen motor symptoms due to lack of dopamine receptor affinity. QT prolongation risk is dose-dependent; monitor ECG at baseline and after dose changes. Avoid use in patients with dementia-related psychosis due to increased mortality risk. A 1-week washout prior to initiation is recommended if switching from other antipsychotics. Dose adjustment required in renal impairment (Cr Cl <30 m L/min).
ACTIQ is a transmucosal immediate-release fentanyl formulation indicated for breakthrough cancer pain in opioid-tolerant patients. Initiate with the lowest strength (200 mcg) and titrate upward. Avoid use in opioid-naive patients due to risk of fatal respiratory depression. Place the unit between cheek and lower gum, not sublingually. Instruct patient not to bite or suck the unit. Monitor for sedation and respiratory depression. Multiple units may be used per episode if needed, but wait at least 4 hours before next episode. Dispose of partially used units by flushing down toilet.
Avoid grapefruit juice as it may increase drug levels.,Report any irregular heartbeat, fainting, or dizziness.,Do not drive or operate heavy machinery until effect on coordination is known.,Take this medication with or without food exactly as prescribed.,Do not stop abruptly without consulting your doctor.
Only use ACTIQ if you are already taking regular around-the-clock opioid pain medicine and are tolerant to opioids.,Do not use ACTIQ for short-term pain like after surgery, headache, or dental pain.,Place the unit in your cheek pouch, not under your tongue. Do not chew or suck it.,If you need more than 4 units per day, contact your doctor as your dose may need adjustment.,Store ACTIQ in a safe place away from children, as accidental ingestion can be fatal.,Dispose of unused or partially used units by flushing them down the toilet.
"Pimavanserin, a serotonin 5-HT2A receptor inverse agonist, may reduce the therapeutic efficacy of apomorphine, a non-ergoline dopamine agonist used for Parkinson's disease. By antagonizing 5-HT2A receptors, pimavanserin could counteract the dopamine-mediated effects of apomorphine, potentially leading to worsened motor control and reduced clinical benefit. This interaction may result in increased Parkinsonian symptoms and decreased response to apomorphine rescue therapy."
"Pimavanserin, a serotonin 5-HT2A receptor inverse agonist, may antagonize the effects of levodopa by blocking 5-HT2A receptors on dopaminergic neurons, potentially reducing the therapeutic efficacy of levodopa in treating Parkinson's disease. This interaction can lead to worsening of motor symptoms and decreased clinical response to levodopa therapy."
"The therapeutic efficacy of Rotigotine can be decreased when used in combination with Pimavanserin."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PIMAVANSERIN vs ACTIQ, answered by our medical review team.
PIMAVANSERIN is a Serotonin Inverse Agonist that works by Pimavanserin is a selective serotonin 5-HT2A receptor inverse agonist and antagonist, with no affinity for dopamine receptors, modulating glutamate and dopamine signaling in the cortex and striatum.. ACTIQ is a Opioid Analgesic that works by Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PIMAVANSERIN and ACTIQ depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PIMAVANSERIN is: 34 mg orally once daily.. The standard adult dose of ACTIQ is: 200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PIMAVANSERIN and ACTIQ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PIMAVANSERIN is classified as Category A/B. Pimavanserin is classified as Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. In animal reproduction studies, no evidence of fetal harm w. ACTIQ is classified as Category C. FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.